- Drug Pipelines
- April 2025
- 280 Pages
Global
From €2650EUR$3,000USD£2,263GBP
- Report
- May 2024
- 140 Pages
Global
From €5740EUR$6,499USD£4,903GBP
- Report
- February 2022
- 308 Pages
Global
From €8390EUR$9,500USD£7,167GBP
- Report
- February 2024
- 88 Pages
Global
From €3500EUR$4,245USD£3,094GBP
Aflibercept is a drug used to treat colon cancer. It is a recombinant fusion protein that binds to and inhibits the activity of vascular endothelial growth factor (VEGF). This helps to reduce the growth of new blood vessels that can feed the tumor and cause it to grow. Aflibercept is used in combination with other chemotherapy drugs to treat metastatic colorectal cancer. It is administered intravenously every two weeks.
Aflibercept is a relatively new drug, having been approved by the US Food and Drug Administration in 2012. It is used in combination with other drugs to treat metastatic colorectal cancer, and is generally well tolerated. Common side effects include fatigue, nausea, and diarrhea.
Aflibercept is marketed by several companies, including Regeneron Pharmaceuticals, Sanofi, and Merck. It is also available in generic form from several generic drug manufacturers. Show Less Read more
